ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
ImmunityBio is making significant strides in its bladder cancer immunotherapy efforts. The company's revenue has seen a substantial increase, driven by the growing adoption of its treatment Anktiva. However, despite this growth, the company continues to face high operating expenses and losses as it invests heavily in its platform.
- ▪ImmunityBio's revenue surged 168% year-over-year to $44.2 million in the first quarter of 2026.
- ▪The adoption of Anktiva among physicians is accelerating, contributing to the company's growth.
- ▪Despite the revenue increase, ImmunityBio reported an adjusted net loss of $86.2 million due to high operating expenses.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907099-immunitybio-one-approval-away-from-a-multi-billion-dollar-breakout"},"author":{"@type":"Person","name":"Petri Dish…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
